RESUMO
BACKGROUND: : The II Brazilian Consensus on Gastric Cancer of the Brazilian Gastric Cancer Association BGCA (Part 1) was recently published. On this occasion, countless specialists working in the treatment of this disease expressed their opinion in the face of the statements presented. AIM: : To present the BGCA Guidelines (Part 2) regarding indications for surgical treatment, operative techniques, extension of resection and multimodal treatment. METHODS: To formulate these guidelines, the authors carried out an extensive and current review regarding each declaration present in the II Consensus, using the Medline/PubMed, Cochrane Library and SciELO databases initially with the following descriptors: gastric cancer, gastrectomy, lymphadenectomy, multimodal treatment. In addition, each statement was classified according to the level of evidence and degree of recommendation. RESULTS: : Of the 43 statements present in this study, 11 (25,6%) were classified with level of evidence A, 20 (46,5%) B and 12 (27,9%) C. Regarding the degree of recommendation, 18 (41,9%) statements obtained grade of recommendation 1, 14 (32,6%) 2a, 10 (23,3%) 2b e one (2,3%) 3. CONCLUSION: : The guidelines complement of the guidelines presented here allows surgeons and oncologists who work to combat gastric cancer to offer the best possible treatment, according to the local conditions available.
Assuntos
Neoplasias Gástricas , Brasil , Consenso , Gastrectomia , Humanos , Excisão de Linfonodo , Neoplasias Gástricas/cirurgiaRESUMO
BACKGROUND: Since the publication of the first Brazilian Consensus on Gastric Cancer (GC) in 2012 carried out by the Brazilian Gastric Cancer Association, new concepts on diagnosis, staging, treatment and follow-up have been incorporated. AIM: This new consensus is to promote an update to professionals working in the fight against GC and to provide guidelines for the management of patients with this condition. METHODS: Fifty-nine experts answered 67 statements regarding the diagnosis, staging, treatment and prognosis of GC with five possible alternatives: 1) fully agree; 2) partially agree; 3) undecided; 4) disagree and 5) strongly disagree A consensus was adopted when at least 80% of the sum of the answers "fully agree" and "partially agree" was reached. This article presents only the responses of the participating experts. Comments on each statement, as well as a literature review, will be presented in future publications. RESULTS: Of the 67 statements, there was consensus in 50 (74%). In 10 declarations, there was 100% agreement. CONCLUSION: The gastric cancer treatment has evolved considerably in recent years. This consensus gathers consolidated principles in the last decades, new knowledge acquired recently, as well as promising perspectives on the management of this disease.
Assuntos
Neoplasias Gástricas , Brasil , Consenso , Humanos , Sociedades MédicasRESUMO
BACKGROUND: The II Brazilian Consensus on Gastric Cancer by the Brazilian Gastric Cancer Association (ABCG) was recently published. On this occasion, several experts in gastric cancer expressed their opinion before the statements presented. AIM: To present the ABCG Guidelines (part 1) regarding the diagnosis, staging, endoscopic treatment and follow-up of gastric cancer patients. METHODS: To forge these Guidelines, the authors carried out an extensive and current review regarding each statement present in the II Consensus, using the Medline/PubMed, Cochrane Library and SciELO databases with the following descriptors: gastric cancer, staging, endoscopic treatment and follow-up. In addition, each statement was classified according to the level of evidence and degree of recommendation. RESULTS: Of the 24 statements, two (8.3%) were classified with level of evidence A, 11 (45.8%) with B and 11 (45.8%) with C. As for the degree of recommendation, six (25%) statements obtained grade of recommendation 1, nine (37.5%) recommendation 2a, six (25%) 2b and three (12.5%) grade 3. CONCLUSION: The guidelines presented here are intended to assist professionals working in the fight against gastric cancer with relevant and current information, granting them to be applied in the daily medical practice.
Assuntos
Endoscopia do Sistema Digestório , Estadiamento de Neoplasias , Neoplasias Gástricas , Brasil , Consenso , Seguimentos , Humanos , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/cirurgiaRESUMO
BACKGROUND: Gastric outlet obstruction (GOO) is one of the main complications in stage IV gastric cancer patients. This condition is usually managed by gastrojejunostomy (GJ). However, gastric partitioning (GP) has been described as an alternative to overcoming possible drawbacks of GJ, such as delayed gastric emptying and tumor bleeding. AIM: To compare the outcomes of patients who underwent GP and GJ for malignant GOO. METHODS: We retrospectively analyzed 60 patients who underwent palliative gastric bypass for unresectable distal gastric cancer with GOO from 2009 to 2018. Baseline clinicopathological characteristics including age, nutritional status, body mass index, and performance status were evaluated. Obstructive symptoms were graded according to GOO score (GOOS). Surgical outcomes evaluated included duration of the procedure, surgical complications, mortality, and length of hospital stay. Acceptance of oral diet after the procedure, weight gain, and overall survival were the long-term outcomes evaluated. RESULTS: GP was performed in 30 patients and conventional GJ in the other 30 patients. The mean follow-up was 9.2 mo. Forty-nine (81.6%) patients died during that period. All variables were similar between groups, with the exception of worse performance status in GP patients. The mean operative time was higher in the GP group (161.2 vs 85.2 min, P < 0.001). There were no differences in postoperative complications and surgical mortality between groups. The median overall survival was 7 and 8.4 mo for the GP and GJ groups, respectively (P = 0.610). The oral acceptance of soft solids (GOOS 2) and low residue or full diet (GOOS 3) were reached by 28 (93.3%) GP patients and 22 (75.9%) GJ patients (P = 0.080). Multivariate analysis demonstrated that GOOS 2 and GOOS 3 were the main prognostic factors for survival (hazard ratio: 8.90, 95% confidence interval: 3.38-23.43, P < 0.001). CONCLUSION: GP is a safe and effective procedure to treat GOO. Compared to GJ, it provides similar surgical outcomes with a trend to better solid diet acceptance by patients.
RESUMO
Peritoneal recurrence is the foremost pattern of failure after potentially curative resection for gastric cancer. Our aim was to evaluate the prognostic value of intraperitoneal free cancer cells (IFCCs) in peritoneal lavage of patients who underwent potentially curative resection for gastric carcinoma. Two hundred twenty patients with gastric cancer stage I, II, or III were prospectively evaluated with peritoneal lavage and cytologic examination. Aspirated fluid from the abdominal cavity was centrifuged and subjected to Papanicolaou staining. The mean age was 60.9 years (range, 21-89 years), and 63.6% were men. IFCCs were detected in 6.8% of the patients; suspicious in 2.7%, and negative in 84.5%. No judgment could be given in 5.9% of the cases. Invasion of the gastric serosa (pT3) was observed in all positive cytology patients. Patients with IFCCs had a mean survival time of 10.5 months, while those with negative IFCC had a mean survival time of 61 months (P = 0.00001). There was no correlation between the presence of IFCCs and tumor size, histology, pN, or tumor site. Our conclusions are that (1) positive cytology indicates a poor prognosis in patients who underwent potentially curative gastric resection and (2) peritoneal lavage cytology improves staging in assessing these patients and may alter their therapeutic approach.
Assuntos
Carcinoma/patologia , Gastrectomia , Cuidados Intraoperatórios , Cavidade Peritoneal/patologia , Lavagem Peritoneal , Neoplasias Gástricas/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma/secundário , Carcinoma/cirurgia , Feminino , Seguimentos , Humanos , Laparotomia , Excisão de Linfonodo , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Estadiamento de Neoplasias , Prognóstico , Estudos Prospectivos , Membrana Serosa/patologia , Neoplasias Gástricas/cirurgia , Taxa de Sobrevida , Resultado do TratamentoRESUMO
INTRODUCTION: Minimally invasive surgery widely used to treat benign disorders of the digestive system, has become the focus of intense study in recent years in the field of surgical oncology. Since then, the experience with this kind of approach has grown, aiming to provide the same oncological outcomes and survival to conventional surgery. Regarding gastric cancer, surgery is still considered the only curative treatment, considering the extent of resection and lymphadenectomy performed. Conventional surgery remains the main modality performed worldwide. Notwithstanding, the role of the minimally invasive access is yet to be clarified. OBJECTIVE: To evaluate and summarize the current status of minimally invasive resection of gastric cancer. METHODS: A literature review was performed using Medline/PubMed, Cochrane Library and SciELO with the following headings: gastric cancer, minimally invasive surgery, robotic gastrectomy, laparoscopic gastrectomy, stomach cancer. The language used for the research was English. RESULTS: 28 articles were considered, including randomized controlled trials, meta-analyzes, prospective and retrospective cohort studies. CONCLUSION: Minimally invasive gastrectomy may be considered as a technical option in the treatment of early gastric cancer. As for advanced cancer, recent studies have demonstrated the safety and feasibility of the laparoscopic approach. Robotic gastrectomy will probably improve outcomes obtained with laparoscopy. However, high cost is still a barrier to its use on a large scale.
INTRODUÇÃO: A cirurgia minimamente invasiva amplamente usada para tratar doenças benignas do aparelho digestivo, tornou-se o foco de intenso estudo nos últimos anos no campo da oncologia cirúrgica. Desde então, a experiência com este tipo de abordagem tem crescido, com o objetivo de fornecer os mesmos resultados oncológicos e sobrevivência à cirurgia convencional. Em relação ao câncer gástrico, o tratamento cirúrgico ainda é considerado o único tratamento curativo, considerando a extensão da ressecção e linfadenectomia realizada. A gastrectomia convencional continua a ser a principal modalidade realizada em todo o mundo. Não obstante, o papel do acesso minimamente invasivo tem ainda de ser esclarecido. OBJETIVO: Avaliar e resumir o estado atual da ressecção minimamente invasiva do câncer gástrico. MÉTODO: Foi realizada revisão da literatura utilizando as bases Medline/PubMed, Cochrane Library e SciELO com os seguintes descritores: câncer gástrico, cirurgia minimamente invasiva, gastrectomia robótica, gastrectomia laparoscópica, neoplasia de estômago. A língua usada para a pesquisa foi o inglês. RESULTADOS: Foram considerados para elaboração desta revisão 28 artigos, entre eles ensaios clínicos randomizados, metanálises, estudos coorte prospectivos e retrospectivos. CONCLUSÃO: A gastrectomia minimamente invasiva é opção técnica no tratamento do câncer gástrico precoce. Quanto ao câncer avançado, estudos recentes têm demonstrado a segurança e a viabilidade do acesso videolaparoscópico. A gastrectomia robótica provavelmente melhorará os resultados obtidos com a laparoscopia. Porém, o alto custo ainda é impedimento para sua utilização em larga escala.
Assuntos
Gastrectomia/métodos , Neoplasias Gástricas/cirurgia , Gastrectomia/normas , Humanos , Procedimentos Cirúrgicos Minimamente Invasivos , Estadiamento de Neoplasias , Procedimentos Cirúrgicos Robóticos , Neoplasias Gástricas/patologiaRESUMO
ABSTRACT Background : The II Brazilian Consensus on Gastric Cancer of the Brazilian Gastric Cancer Association BGCA (Part 1) was recently published. On this occasion, countless specialists working in the treatment of this disease expressed their opinion in the face of the statements presented. Aim : To present the BGCA Guidelines (Part 2) regarding indications for surgical treatment, operative techniques, extension of resection and multimodal treatment. Methods: To formulate these guidelines, the authors carried out an extensive and current review regarding each declaration present in the II Consensus, using the Medline/PubMed, Cochrane Library and SciELO databases initially with the following descriptors: gastric cancer, gastrectomy, lymphadenectomy, multimodal treatment. In addition, each statement was classified according to the level of evidence and degree of recommendation. Results : Of the 43 statements present in this study, 11 (25,6%) were classified with level of evidence A, 20 (46,5%) B and 12 (27,9%) C. Regarding the degree of recommendation, 18 (41,9%) statements obtained grade of recommendation 1, 14 (32,6%) 2a, 10 (23,3%) 2b e one (2,3%) 3. Conclusion : The guidelines complement of the guidelines presented here allows surgeons and oncologists who work to combat gastric cancer to offer the best possible treatment, according to the local conditions available.
RESUMO Racional: O II Consenso Brasileiro de Câncer Gástrico da Associação Brasileira de Câncer Gástrico ABCG (Parte 1) foi recentemente publicado. Nesta ocasião inúmeros especialistas que atuam no tratamento desta doença expressaram suas opiniões diante declarações apresentadas. Objetivo: Apresentar as Diretrizes da ABCG (Parte 2) quanto às indicações de tratamento cirúrgico, técnicas operatórias, extensão de ressecção e terapia combinada. Métodos: Para formulação destas diretrizes os autores realizaram extensa e atual revisão referente a cada declaração presente no II Consenso, utilizando as bases Medline/PubMed, Cochrane Library e SciELO, inicialmente com os seguintes descritores: câncer gástrico, gastrectomia, linfadenectomia, terapia combinada. Ainda, cada declaração foi classificada de acordo com o nível de evidência e grau de recomendação. Resultados: Das 43 declarações presentes neste estudo, 11 (25,6%) foram classificadas com nível de evidência A, 20 (46,5%) B e 12 (27,9%) C. Quanto ao grau de recomendação, 18 (41,9%) declarações obtiveram grau de recomendação 1, 14 (32,6%) 2a, 10 (23,3%) 2b e um (2,3%) 3. Conclusão: O complemento das diretrizes aqui presentes possibilita que cirurgiões e oncologistas que atuam no combate ao câncer gástrico possam oferecer o melhor tratamento possível, de acordo com as condições locais disponíveis.
Assuntos
Humanos , Neoplasias Gástricas/cirurgia , Brasil , Consenso , Gastrectomia , Excisão de LinfonodoRESUMO
The II Brazilian Consensus on Gastric Cancer by the Brazilian Gastric Cancer Association (ABCG) was recently published. On this occasion, several experts in gastric cancer expressed their opinion before the statements presented. Aim: To present the ABCG Guidelines (part 1) regarding the diagnosis, staging, endoscopic treatment and follow-up of gastric cancer patients. Methods: To forge these Guidelines, the authors carried out an extensive and current review regarding each statement present in the II Consensus, using the Medline/PubMed, Cochrane Library and SciELO databases with the following descriptors: gastric cancer, staging, endoscopic treatment and follow-up. In addition, each statement was classified according to the level of evidence and degree of recommendation. Results: Of the 24 statements, two (8.3%) were classified with level of evidence A, 11 (45.8%) with B and 11 (45.8%) with C. As for the degree of recommendation, six (25%) statements obtained grade of recommendation 1, nine (37.5%) recommendation 2a, six (25%) 2b and three (12.5%) grade 3. Conclusion: The guidelines presented here are intended to assist professionals working in the fight against gastric cancer with relevant and current information, granting them to be applied in the daily medical practice.
O II Consenso Brasileiro de Câncer Gástrico da Associação Brasileira de Câncer Gástrico (ABCG) foi recentemente publicado. Nesta ocasião, inúmeros especialistas que atuam no tratamento desta doença expressaram sua opinião diante declarações apresentadas. Objetivo: Apresentar as Diretrizes da ABCG (Parte 1) quanto ao diagnóstico, estadiamento, tratamento endoscópico e seguimento dos pacientes com câncer gástrico. Métodos: Para formulação destas Diretrizes os autores realizaram extensa e atual revisão referente a cada declaração presente no II Consenso, utilizando as bases Medline/PubMed, Cochrane Library e SciELO com os seguintes descritores: câncer gástrico, estadiamento, tratamento endoscópico e seguimento. Ainda, cada declaração foi classificada de acordo com o nível de evidência e grau de recomendação. Resultados: Das 24 declarações, duas (8,3%) foram classificadas com nível de evidência A, 11 (45,8%) B e 11 (45,8%) C. Quanto ao grau de recomendação, seis (25%) declarações obtiveram grau de recomendação 1, nove (37,5%) grau 2a, seis (25%) 2b e três (12,5%) 3. Conclusão: As diretrizes aqui presentes têm a finalidade de auxiliar os profissionais que atuam no combate ao câncer gástrico com informações relevantes e atuais, permitindo que sejam aplicadas na prática médica diária.
Assuntos
Humanos , Neoplasias Gástricas/diagnóstico , Endoscopia/métodos , Estadiamento de Neoplasias/métodos , Seguimentos , Conferência de ConsensoRESUMO
ABSTRACT Background: Since the publication of the first Brazilian Consensus on Gastric Cancer (GC) in 2012 carried out by the Brazilian Gastric Cancer Association, new concepts on diagnosis, staging, treatment and follow-up have been incorporated. Aim: This new consensus is to promote an update to professionals working in the fight against GC and to provide guidelines for the management of patients with this condition. Methods: Fifty-nine experts answered 67 statements regarding the diagnosis, staging, treatment and prognosis of GC with five possible alternatives: 1) fully agree; 2) partially agree; 3) undecided; 4) disagree and 5) strongly disagree A consensus was adopted when at least 80% of the sum of the answers "fully agree" and "partially agree" was reached. This article presents only the responses of the participating experts. Comments on each statement, as well as a literature review, will be presented in future publications. Results: Of the 67 statements, there was consensus in 50 (74%). In 10 declarations, there was 100% agreement. Conclusion: The gastric cancer treatment has evolved considerably in recent years. This consensus gathers consolidated principles in the last decades, new knowledge acquired recently, as well as promising perspectives on the management of this disease.
RESUMO Racional: Desde a publicação do primeiro Consenso Brasileiro sobre Câncer Gástrico em 2012 realizado pela Associação Brasileira de Câncer Gástrico (ABCG), novos conceitos sobre o diagnóstico, estadiamento, tratamento e seguimento foram incorporados. Objetivo: Promover uma atualização aos profissionais que atuam no combate ao câncer gástrico (CG) e fornecer diretrizes quanto ao manejo dos pacientes portadores desta afecção. Métodos: Cinquenta e nove especialistas responderam 67 declarações sobre o diagnóstico, estadiamento, tratamento e prognóstico do CG com cinco alternativas possíveis: 1) concordo plenamente; 2) concordo parcialmente; 3) indeciso; 4) discordo e 5) discordo fortemente. Foi considerado consenso a concordância de pelo menos 80% da soma das respostas "concordo plenamente" e "concordo parcialmente". Este artigo apresenta apenas as respostas dos especialistas participantes. Os comentários sobre cada declaração, assim como uma revisão da literatura serão apresentados em publicações futuras. Resultados: Das 67 declarações, houve consenso em 50 (74%). Em 10 declarações, houve concordância de 100%. Conclusão: O tratamento do câncer gástrico evoluiu consideravelmente nos últimos anos. Este consenso reúne princípios consolidados nas últimas décadas, novos conhecimentos adquiridos recentemente, assim como perspectivas promissoras sobre o manejo desta doença.
Assuntos
Humanos , Neoplasias Gástricas , Sociedades Médicas , Brasil , ConsensoRESUMO
BACKGROUND: In Brazil, gastric cancer is the fourth most common malignancy among men and sixth among women. The cause is multivariate and the risks are well known. It has prognosis and treatment defined by the location and staging of the tumor and number of lymph nodes resected and involved. AIM: The Brazilian Consensus on Gastric Cancer promoted by ABCG was designed with the intention to issue guidelines that can guide medical professionals to care for patients with this disease. METHODS: Were summarized and answered 43 questions reflecting consensus or not on diagnosis and treatment that may be used as guidance for its multidisciplinary approach. The method involved three steps. Initially, 56 digestive surgeons and related medical specialties met to formulate the questions that were sent to participants for answers on scientific evidence and personal experience. Summaries were presented, discussed and voted in plenary in two other meetings. They covered 53 questions involving: diagnosis and staging (six questions); surgical treatment (35 questions); chemotherapy and radiotherapy (seven questions) and anatomopathology, immunohistochemistry and perspective (five questions). It was considered consensus agreement on more than 70% of the votes in each item. RESULTS: All the answers were presented and voted upon, and in 42 there was consensus. CONCLUSION: It could be developed consensus on most issues that come with the care of patients with gastric cancer and they can be transformed in guidelines.
Assuntos
Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/terapia , Brasil , HumanosRESUMO
BACKGROUND: Eastern literature is remarkable for presenting survival rates for surgical treatment of gastric adenocarcinoma superior to those presented in western countries. AIM: To analyze the long-term result after D2 gastrectomy for gastric cancer. METHODS: Two hundred seventy four underwent gastrectomy with D2 lymph node dissection as exclusive treatment. The inclusion criteria were: 1) lymph node removal according to Japanese standardized lymphatic chain dissection; 2) potentially curative surgery described in medical records as D2 or more lymph node dissection; 3) tumoral invasiveness of gastric wall restricted to the organ (T1-T3); 4) absence of distant metastasis (N0-N2/M0); 5) a minimum of five years follow-up. Clinical pathological data included sex, age, tumor location, Borrmann's macroscopic tumor classification, type of gastrectomy, mortality rates, hystological type, TNM classification and staging according to UICC TNM 1997. RESULTS: Total gastrectomy was performed in 77 cases (28.1%) and subtotal gastrectomy in 197 (71.9%). The tumor was located in the upper third in 28 cases (10.2%), in the middle third in 53 (19.3%), and in the lower third in 182 (66.5%). Among patients that had their Borrmann's classification assigned, five cases (1.8%) were BI, 34 (12.4%) BII, 230 (84.0%) BIII and 16 (5.9%) BIV. Tumors were histologically classified as Laurén intestinal type in 119 cases (43.4%) and as diffuse type in 155 (56.6%). According to UICC TNM 1997 classification, early gastric cancer (T1) was diagnosed in 68 cases (24.8 %); 51 (18.6%) were T2, and 155 (56.6%) were T3. No lymph node involvement (N0) was observed in 129 cases (47.1%), whereas 100 (36.5%) were N1 (1-6 lymph nodes), and 45 (16.4%) were N2 (7-15 lymph nodes).The median number of lymph nodes dissected was 35. The overall long-term (five-year) survival rate, for stages I to IIIb was 70.4%. CONCLUSION: Digestive surgeons must be stimulated in performing D2 gastrectomies to avoid wasting the only treatment to gastric adenocarcinoma that has proven to be efficient up to this days. It must be emphasized that standardized lymph nodes dissection according to tumor location is more important that only the number of removed nodes.
Assuntos
Gastrectomia/métodos , Excisão de Linfonodo/métodos , Neoplasias Gástricas/cirurgia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Neoplasias Gástricas/patologia , Adulto JovemRESUMO
ABSTRACT Introduction: Minimally invasive surgery widely used to treat benign disorders of the digestive system, has become the focus of intense study in recent years in the field of surgical oncology. Since then, the experience with this kind of approach has grown, aiming to provide the same oncological outcomes and survival to conventional surgery. Regarding gastric cancer, surgery is still considered the only curative treatment, considering the extent of resection and lymphadenectomy performed. Conventional surgery remains the main modality performed worldwide. Notwithstanding, the role of the minimally invasive access is yet to be clarified. Objective: To evaluate and summarize the current status of minimally invasive resection of gastric cancer. Methods: A literature review was performed using Medline/PubMed, Cochrane Library and SciELO with the following headings: gastric cancer, minimally invasive surgery, robotic gastrectomy, laparoscopic gastrectomy, stomach cancer. The language used for the research was English. Results: 28 articles were considered, including randomized controlled trials, meta-analyzes, prospective and retrospective cohort studies. Conclusion: Minimally invasive gastrectomy may be considered as a technical option in the treatment of early gastric cancer. As for advanced cancer, recent studies have demonstrated the safety and feasibility of the laparoscopic approach. Robotic gastrectomy will probably improve outcomes obtained with laparoscopy. However, high cost is still a barrier to its use on a large scale.
RESUMO Introdução: A cirurgia minimamente invasiva amplamente usada para tratar doenças benignas do aparelho digestivo, tornou-se o foco de intenso estudo nos últimos anos no campo da oncologia cirúrgica. Desde então, a experiência com este tipo de abordagem tem crescido, com o objetivo de fornecer os mesmos resultados oncológicos e sobrevivência à cirurgia convencional. Em relação ao câncer gástrico, o tratamento cirúrgico ainda é considerado o único tratamento curativo, considerando a extensão da ressecção e linfadenectomia realizada. A gastrectomia convencional continua a ser a principal modalidade realizada em todo o mundo. Não obstante, o papel do acesso minimamente invasivo tem ainda de ser esclarecido. Objetivo: Avaliar e resumir o estado atual da ressecção minimamente invasiva do câncer gástrico. Método: Foi realizada revisão da literatura utilizando as bases Medline/PubMed, Cochrane Library e SciELO com os seguintes descritores: câncer gástrico, cirurgia minimamente invasiva, gastrectomia robótica, gastrectomia laparoscópica, neoplasia de estômago. A língua usada para a pesquisa foi o inglês. Resultados: Foram considerados para elaboração desta revisão 28 artigos, entre eles ensaios clínicos randomizados, metanálises, estudos coorte prospectivos e retrospectivos. Conclusão: A gastrectomia minimamente invasiva é opção técnica no tratamento do câncer gástrico precoce. Quanto ao câncer avançado, estudos recentes têm demonstrado a segurança e a viabilidade do acesso videolaparoscópico. A gastrectomia robótica provavelmente melhorará os resultados obtidos com a laparoscopia. Porém, o alto custo ainda é impedimento para sua utilização em larga escala.
Assuntos
Humanos , Neoplasias Gástricas/cirurgia , Gastrectomia/métodos , Neoplasias Gástricas/patologia , Procedimentos Cirúrgicos Minimamente Invasivos , Procedimentos Cirúrgicos Robóticos , Gastrectomia/normas , Estadiamento de NeoplasiasRESUMO
RACIONAL: A literatura oriental é notável por apresentar taxas de sobrevida para o tratamento cirúrgico do adenocarcinoma gástrico superiores àquelas apresentadas nos países ocidentais. OBJETIVO: Analisar o resultado a longo prazo após a gastrectomia D2 por câncer gástrico. MÉTODOS: Duzentos e setenta e quatro pacientes foram submetidos à gastrectomia com dissecção linfonodal D2 como tratamento exclusivo. Os critérios de inclusão foram: 1) remoção dos linfonodos de acordo com dissecção linfática padronizada Japonesa, 2) operação potencialmente curativa descrita no prontuário como dissecção D2 ou mais linfonodos; 3) invasão tumoral da parede gástrica restrita ao órgão (T1-T3); 4) ausência de metástases à distância (N0-N2/M0); 5) mínimo de cinco anos de acompanhamento. Dados clinicopatológicos incluíam sexo, idade, localização do tumor, classificação de Borrmann do tumor macroscópico, o tipo de gastrectomia, as taxas de mortalidade, tipo histológico, classificação e estadiamento TNM de acordo com a UICC TNM 1997. RESULTADOS: Gastrectomia total foi realizada em 77 casos (28,1%) e subtotal em 197 (71,9%). O tumor foi localizado no terço superior em 28 casos (10,2%), no terço médio em 53 (19,3%), e no terço inferior em 182 (66,5%). Borrmann foi atribuído cinco casos (1,8%) como BI, 34 (12,4%) BII, 230 (84,0%) BIII e 16 (5,9%) BIV. Os tumores foram histologicamente classificados como Laurén tipo intestinal em 119 casos (43,4%) e como o tipo difuso em 155 (56,6%). De acordo com a UICC TNM foram câncer gástrico precoce (T1) foi diagnosticada em 68 casos (24,8%); 51 (18,6%) T2 e 155 (56,6%) T3. Nenhum envolvimento linfonodal (N0) foi observado em 129 casos (47,1%), enquanto 100 (36,5%) eram N1 (1-6 linfonodos) e 45 (16,4%) N2 (7-15 gânglios linfáticos). O número médio de linfonodos dissecados foi de 35. A sobrevida em cinco anos para os estádios de I a III B foi de 70,4%. CONCLUSÃO: Cirurgiões digestivos devem ser estimulados a realizarem gastrectomias ...
BACKGROUND: Eastern literature is remarkable for presenting survival rates for surgical treatment of gastric adenocarcinoma superior to those presented in western countries. AIM: To analyze the long-term result after D2 gastrectomy for gastric cancer. METHODS: Two hundred seventy four underwent gastrectomy with D2 lymph node dissection as exclusive treatment. The inclusion criteria were: 1) lymph node removal according to Japanese standardized lymphatic chain dissection; 2) potentially curative surgery described in medical records as D2 or more lymph node dissection; 3) tumoral invasiveness of gastric wall restricted to the organ (T1 - T3); 4) absence of distant metastasis (N0-N2/M0); 5) a minimum of five years follow-up. Clinical pathological data included sex, age, tumor location, Borrmann's macroscopic tumor classification, type of gastrectomy, mortality rates, hystological type, TNM classification and staging according to UICC TNM 1997. RESULTS: Total gastrectomy was performed in 77 cases (28.1%) and subtotal gastrectomy in 197 (71.9%). The tumor was located in the upper third in 28 cases (10.2%), in the middle third in 53 (19.3%), and in the lower third in 182 (66.5%). Among patients that had their Borrmann's classification assigned, five cases (1.8%) were BI, 34 (12.4%) BII, 230 (84.0%) BIII and 16 (5.9%) BIV. Tumors were histologically classified as Laurén intestinal type in 119 cases (43.4%) and as diffuse type in 155 (56.6%). According to UICC TNM 1997 classification, early gastric cancer (T1) was diagnosed in 68 cases (24.8 %); 51 (18.6%) were T2, and 155 (56.6%) were T3. No lymph node involvement (N0) was observed in 129 cases (47.1%), whereas 100 (36.5%) were N1 (1-6 lymph nodes), and 45 (16.4%) were N2 (7-15 lymph nodes).The median number of lymph nodes dissected was 35. The overall long-term (five-year) survival rate, for stages I to IIIb was 70.4%. CONCLUSION: Digestive surgeons must be stimulated in performing D2 gastrectomies ...
Assuntos
Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Gastrectomia/métodos , Excisão de Linfonodo/métodos , Neoplasias Gástricas/cirurgia , Seguimentos , Metástase Linfática , Neoplasias Gástricas/patologiaRESUMO
RACIONAL: A causa do câncer gástrico (CG) é controversa e tem vários fatores envolvidos no seu processo de carcinogênese, incluindo o Helicobacter pylori (Hp) O papel da infecção pelo Hp no CG permanece incerto, com vários estudos controversos. OBJETIVO: Correlacionar a presença da infecção pelo Hp com câncer gástrico, através de exame anatomopatológico convencional do estômago ressecado. MÉTODO: Noventa e um pacientes tratados por ressecção cirúrgica foram revistos. O exame anatomopatológico foi feito em todos os pacientes para determinar a presença de infecção por Hp, metaplasia intestinal (MI) e confirmação do tipo histológico por hematoxilina-eosina. A análise estatística foi realizada através do qui-quadrado e testes de log-rank. RESULTADOS: MI foi observada em 81 tumores (89 por cento). Em geral, a presença de infecção pelo Hp foi observada em 46 casos (50,5 por cento). Não houve associação entre idade e Hp. Nos grupos de pacientes com CG avançado e precoce, a infecção pelo Hp estava presente em 47,7 por cento e 54 por cento dos tumores. A infecção pelo Hp ocorreu em 40 tumores (49 por cento) no grupo de pacientes com MI. Nos com tumores sem MI, Hp estava presente em cinco (50 por cento). Tumores proximais tiveram mais infecção por Hp, quando comparados aos tumores distais. CONCLUSÕES: A taxa de infecção não teve associação significativa com o tipo histológico, sexo, MI ou estágio de desenvolvimento tumoral. Esses resultados podem indicar que a participação da infecção pelo Hp durante o desenvolvimento do CG não pode ser descartada; no entanto, provavelmente não é essencial em todas as fases e o mecanismo do CG pode ser distinto da gastrite crônica e MI. Finalmente, é possível que a associação proposta é mera coincidência e que não há nenhuma influência real das bactérias no processo de carcinogênese.
INTRODUCTION: Etiology of gastric cancer (GC) remains controversial and several factors have implicated in its carcinogenesis process, including Helicobacter pylori (Hp) infection. Hp infection's role on GC remains uncertain, with several conflicting studies. METHOD: Ninety-one patients with diagnosis of adenocarcinoma of the stomach treated by surgical resection were reviewed. Pathological examination was repeated in all patients to determine the presence of Hp infection, intestinal metaplasia (IM) and confirmation of the hystologic type by conventional haematoxylin-eosin staining. Statistical analysis was performed using Chi-quadrate and log-rank tests. RESULTS: IM was observed in 81 tumours (89 percent). Overall, the presence of Hp infection was observed in 46 tumours (50.5 percent). There was no association between age and Hp status. In the group of patients with early and advanced GC, Hp infection was present in 47.7 percent and 54 percent of tumours. Hp infection was present in 40 tumours (49 percent) in the group of patients with IM. In patients with tumours without IM Hp was present in five (50 percent) tumours. Proximal tumours had more Hp infection when compared to distal tumours. CONCLUSIONS: The infection rate had no significant association with histologic type, IM, gender or stage. These results may indicate that participation of Hp infection during GC development cannot be ruled out; however, it is probably not essential during all stages of GC development and the mechanism may be distinct of the chronic gastritis and IM progression. Finally, it is possible that the proposed association is merely coincidental and that there is no actual influence of the bacteria in the carcinogenesis process.
RESUMO
Inflammatory Bowel Diseases - ulcerative colitis and Crohn's disease- are chronic gastrointestinal inflammatory diseases of unknown etiology. Decreased oral intake, malabsorption, accelerated nutrient losses, increased requirements, and drug-nutrient interactions cause nutritional and functional deficiencies that require proper correction by nutritional therapy. The goals of the different forms of nutritional therapy are to correct nutritional disturbances and to modulate inflammatory response, thus influencing disease activity. Total parenteral nutrition has been used to correct and to prevent nutritional disturbances and to promote bowel rest during active disease, mainly in cases of digestive fistulae with high output. Its use should be reserved for patients who cannot tolerate enteral nutrition. Enteral nutrition is effective in inducing clinical remission in adults and promoting growth in children. Due to its low complication rate and lower costs, enteral nutrition should be preferred over total parenteral nutrition whenever possible. Both present equal effectiveness in primary therapy for remission of active Crohn's disease. Nutritional intervention may improve outcome in certain individuals; however, because of the costs and complications of such therapy, careful selection is warranted, especially in patients presumed to need total parenteral nutrition. Recent research has focused on the use of nutrients as primary treatment agents. Immunonutrition is an important therapeutic alternative in the management of inflammatory bowel diseases, modulating the inflammation and changing the eicosanoid synthesis profile. However, beneficial reported effects have yet to be translated into the clinical practice. The real efficacy of these and other nutrients (glutamine, short-chain fatty acids, antioxidants) still need further evaluation through prospective and randomized trials.
Assuntos
Doenças Inflamatórias Intestinais/dietoterapia , Distúrbios Nutricionais/dietoterapia , Apoio Nutricional/métodos , Colite Ulcerativa/complicações , Colite Ulcerativa/dietoterapia , Doença de Crohn/complicações , Doença de Crohn/dietoterapia , Humanos , Doenças Inflamatórias Intestinais/complicações , Distúrbios Nutricionais/etiologia , Distúrbios Nutricionais/prevenção & controleRESUMO
BACKGROUND: Gastric cancer (GC) is a predominately male disease. Usually for every female that suffers from this condition there are two males and occurred an increase in the number of females in last decades. Brazil is poor in data about this issue. AIM: To verify if in Brazil it happened: a) a change in the gender ratio and on the average age of the patients; b) an increase in the number of patients with 70 years of age or more suffering from this disease; c) changes in the gender ratio and in the average age in the several gastric locations during the period of study. METHODS: The medical history of patients diagnosed with primary gastric adenocarcinoma, between 1971 and 1998 were obtained at Hospital das Clínicas of the University of São Paulo, São Paulo, SP, Brazil. Exclusion criteria were: patients suffering from a non epithelial gastric malignancy; adenocarcinoma from the intestinal metaplasia in the distal esophagus invading the proximal stomach and patients submitted to a gastric resection, due to a benign or malignant tumor during the last five years prior to the surgical procedure analyzed in this study. The patients were divided into 10 years age groups and also divided in three groups, according to their ages and time intervals. Interrelationships between gender and age, and with tumor´s location on gastric wall were analyzed. RESULTS: From 1971 to 1998, 1578 patients with GC were hospitalized. Among them, 1021 were treated with gastric resection, corresponding to 64.7 percent of all patients. There was an increase in the proportion of patients older than 70 years, and decrease between 41 and 70 years. There was no statistical significant difference among the average ages and the different locations. There were significant differences for the locations favoring proximal third and stump, both more prevalent in males. CONCLUSIONS: a) Occurred modifications in the ratio between genders: greater number of women and an increase in the number of male patients in the age group between 41 and 70 years; b) it was proved the greater number of occurrences in patients over 70 years of age; c) there was a greater increase in the male predominance in the tumors located in the stomach´s proximal third.
RACIONAL: O câncer gástrico é afecção predominantemente masculina. Para cada mulher há dois homens, mas tem ocorrido aumento de casos em mulheres nas últimas décadas. O Brasil é pobre em dados sobre esse tema. OBJETIVO: Verificar se no Brasil em relação ao câncer gástrico ocorreu: a) mudança na relação entre os sexos; b) aumento no número de pacientes com mais de 70 anos portadores da doença; c) alteração na relação gênero e média de idade nas variadas localizações do tumor. METODOS: Prontuários de pacientes com adenocarcinoma do estômago 1971 e 1998 foram obtidos no Hospital das Clínicas da Universidade de São Paulo, Brasil com os seguintes critérios de exclusão: pacientes portadores de doença não epitelial; adenocarcinoma de metaplasia intestinal no esôfago distal invadindo cárdia e pacientes submetidos à ressecção gástrica durante os últimos cinco anos anteriores ao período de estudo. Foram divididos em intervalos de 10 anos e também em três grupos de acordo com suas idades e intervalo de tempo. Foram analisadas inter-relações entre sexo e idade, e a localização do tumor em relação à parte anatômica do órgão. RESULTADOS: De 1971 a 1998, 1578 pacientes foram hospitalizados com câncer do estômago. Dentre eles, 1021 foram tratados com ressecção gástrica (64,7 por cento). Houve aumento na proporção de pacientes com mais de 70 anos e diminuição entre a faixa de 41 a 70. Não houve diferença estatística entre a idade e as várias localizações. Houve diferença significante favorecendo a localização proximal e coto gástrico, ambas mais prevalentes nos homens. CONCLUSÕES: a) Ocorreram modificações na relação entre os sexos: maior número de mulheres e aumento no número de homens na idade entre 41 e 70; b) demonstrou-se aumento no número de pacientes com mais de 70 anos; c) houve aumento da prevalência de tumores na parte proximal do estômago e maior nos homens.
RESUMO
BACKGROUND: Advanced gastric cancer carries a poor-prognosis. The best extent of the node dissection and the value of postoperative adjuvant treatments remain open questions.AIM: To study the efficacy of adjuvant chemoradiation and the prognostic value of some clinico-pathological variables in gastric cancer previously submitted to surgery.METHODS: Retrospective single institution study of 69 patients with histological diagnoses of gastric adenocarcinoma, consecutively submitted to radical surgery with curative intent in a five years period. Lymph node dissection was either D1 or D2 at the surgeon's description. All patients were submitted to adjuvant chemoradiation according to MacDonald et al.2. Treatment discontinuation and early deaths were considered as serious toxic events. Clinical-pathological variables (the extent D level of the node dissection, T/N-stage, histological subtype, margin status, number of the dissected nodes) were correlated to the results. Overall survival was estimated according to the Kaplan-Meier method and the curves were compared by the log-rank test.RESULTS: Patients characteristics: 48 male/21 female, median age 56,4 y (30-79). In 25 patients, the extent of node dissection was D1, in 41 was D2 and D0 in 3. Staging (n): T2 (16); T3 (49); T4 (4); No (11); N1 (29); N2 (20); N3 (8); Nx (1). Histological subtype: intestinal (45), diffuse (19) and unknown (5). Margins were free in 57 patients, the median number of dissected nodes was 31 (0-120). They were treated with linear acelerator 6 MV photons, AP/PA fields with 45Gy in 5 weeks in 90% of the patients and the treatment was done in a mean time of 19,2 weeks. In the median follow-up of 19,3mo (8-52,5mo), 52 patients with more than 24 months of follow-up occurred 38 deaths. The median overall survival for all patients was 22,2 months. Seven (10%) patients presented serious toxic events and treatment was discontinued...
RACIONAL: Câncer gástrico avançado é sempre acompanhado de pobre prognóstico. A melhor forma de ser realizada a linfadenectomia e o valor da radioquimioterapia adjuvante ainda estão em tela de juízo.OBJETIVO: Estudar a eficácia da terapia adjuvante e o valor prognóstico de algumas variáveis clínico-patológicas nos pacientes submetidos à ressecção cirúrgica de seus tumores.MÉTODOS: Estudo retrospectivo de uma única instituição hospitalar incluindo 69 pacientes com diagnóstico histológico de adenocarcinoma gástrico consecutivamente submetidos à operação radical com intenção curativa no período de cinco anos. Linfadenectomia foi tanto D1 como D2 e em todos os pacientes foi aplicado o protocolo quimioradioterápico proposto por Macdonald et al.2. Interrupção do tratamento bem como mortes precoces foram consideradas eventos tóxicos sérios. Variáveis clínico-patológicas (extensão do D, estadiamento T/N, subtipos histológicos e número de linfonodos ressecados), foram correlacionados com os resultados. A sobrevida total foi estimada de acordo com o método de Kaplan-Meier.RESULTADOS: Foram 48 homens e 21 mulheres, com idade média de 56,4 anos. Em 25 pacientes a extensão da linfadenectomia foi D1; em 41, D2 e em 3, D0. O estadiamento T2 foi em 16 pacientes; T3 em 49; T4 em 4; N0 em 11; N1 em 29; N2 em 20; N3 em 8; Nx em 1. O subtipo histológico intestinal ocorreu em 45; o difuso em 19 e desconhecido em 5. Em 57 pacientes as margens estavam livres de tumor e foram ressecados em média 31 linfonodos. Foram tratados por acelerador linear 6 MV, AP/PA campos com 45Gy em cinco semanas em 90% dos casos com média de tratamento de 19,2 semanas. No tempo médio de seguimento de 19,3 meses, entre 52 pacientes com mais de 24 meses foram observadas 38 mortes. O tempo médio geral de sobrevida do grupo como um todo foi de 22,2 meses. Sete (10%) apresentaram eventos tóxicos sérios e o tratamento foi interrompido...
Assuntos
Humanos , Masculino , Feminino , Adenocarcinoma , Estadiamento de Neoplasias , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/radioterapia , Prognóstico , Quimioterapia Adjuvante , SeguimentosRESUMO
RACIONAL: A esplenectomia no tratamento do câncer gástrico avançado é advogada com o intuito de se realizar toalete linfonodal adequada, porém, seu benefício tem sido questionado ultimamente por estudos que a relacionam com aumento da morbimortalidade. OBJETIVO: Avaliar os resultados da associação da gastrectomia total D2 e esplenectomia correlacionando-os com a média dos resultados dos atendimentos sem ela. MÉTODOS: Análise retrospectiva de planilha prospectiva de pacientes com adenocarcinoma gástrico avançado submetidos à gastrectomia total com linfadenectomia a D2 e esplenectomia entre 1985 e 2005 no Serviço de Cirurgia do Estômago do HCFMUSP. RESULTADOS: Ao todo, 109 pacientes submetidos à gastrectomia total com linfadenectomia D2 foram inclusos no estudo nos quais foi realizada a esplenectomia associadamente. Destes, foi realizada ressecção concomitante de outros órgãos, em 43 pacientes (41 pancreatectomias, 5 colectomias segmentares e 3 hepatectomias). Em 39% dos casos foram observadas complicações pós-operatórias, incidência significativamente maior do que a média global do Serviço (24%). Em 10 (9,1%) pacientes foi verificada a ocorrência de abscessos intra-abdominais. Dez pacientes foram a óbito (9,1%), todos devido a complicações sépticas superiores à média global do Serviço de 3,7%. Foram observadas metástases para as cadeias 10 e 11d em 13 (11,9%) pacientes, sendo a ocorrência maior nos tumores do terço superior (19,5%) e nos tumores T4 (20%). CONCLUSÃO: A esplenectomia no tratamento do câncer gástrico está relacionada a aumento da morbimortalidade, devendo ser reservada para pacientes com tumores avançados localizados nas porções proximais do estômago.
BACKGROUND: Splenectomy in the treatment of gastric cancer is employed to achieve an adequate lymph nodal resection; however, its benefits has been questioned by studies relating it with a higher mortality and morbidity. AIM: To evaluate the results associated with total D2 gastrectomy and splenectomy, correlating these with the average results obtained from patients without this procedure. METHODS: Retrospective analysis from a prospective database of the patients with gastric adenocarcinoma submitted to total gastrectomy and D2 lymphadenectopmy plus splenectomy between 1985 and 2005 in the Gastrointestinal Surgery Division of the Medical School of São Paulo University. RESULTS: A total of 109 patients were enrolled in this study. Resection of other organs was performed in 43 patients (41 pancreatectomies, 5 transverse colectomies and 3 hepatectomies). The incidence of post-operative complications was 39%, higher than the expected from our overall morbidity (24%). Intra cavitary abscesses were found on 10 patients (9.1%). Ten patients died (9.1%), all due to septic complications significantly different of the overall mortality of 3.7%, registered in our Division. Metastasis to station 10 and 11d were observed on 13 patients (11.9%), with higher risk related to T4 lesions (20%) and tumors of the upper third (19.5%). CONCLUSION: Splenectomy in the treatment of gastric cancer is related to a higher morbidity and mortality rates, and should be reserved to advanced tumors in the upper part of the stomach.
RESUMO
Inflammatory Bowel Diseases - ulcerative colitis and Crohn's disease- are chronic gastrointestinal inflammatory diseases of unknown etiology. Decreased oral intake, malabsorption, accelerated nutrient losses, increased requirements, and drug-nutrient interactions cause nutritional and functional deficiencies that require proper correction by nutritional therapy. The goals of the different forms of nutritional therapy are to correct nutritional disturbances and to modulate inflammatory response, thus influencing disease activity. Total parenteral nutrition has been used to correct and to prevent nutritional disturbances and to promote bowel rest during active disease, mainly in cases of digestive fistulae with high output. Its use should be reserved for patients who cannot tolerate enteral nutrition. Enteral nutrition is effective in inducing clinical remission in adults and promoting growth in children. Due to its low complication rate and lower costs, enteral nutrition should be preferred over total parenteral nutrition whenever possible. Both present equal effectiveness in primary therapy for remission of active Crohn's disease. Nutritional intervention may improve outcome in certain individuals; however, because of the costs and complications of such therapy, careful selection is warranted, especially in patients presumed to need total parenteral nutrition. Recent research has focused on the use of nutrients as primary treatment agents. Immunonutrition is an important therapeutic alternative in the management of inflammatory bowel diseases, modulating the inflammation and changing the eicosanoid synthesis profile. However, beneficial reported effects have yet to be translated into the clinical practice. The real efficacy of these and other nutrients (glutamine, short-chain fatty acids, antioxidants) still need further evaluation through prospective and randomized trials
Assuntos
Humanos , Doenças Inflamatórias Intestinais , Distúrbios Nutricionais , Apoio Nutricional , Colite Ulcerativa , Doença de Crohn , Doenças Inflamatórias Intestinais , Distúrbios NutricionaisRESUMO
Os autores relatam caso de um homem de 37 anos de idade submetido a laparotomia para retirada de massa indolor em fossa ilíaca esquerda, com diagnóstico histopatológico de fibromatose intra-abdominal, entidade rara, de difícil planejamento terapêutico, com recidiva freqüente, agressiva localmente, ocasionando taxa de morbiletalidade bem definidas na literatura. Os exames de imagem realizados e seu papel no diagnóstico são aqui discutidos.